BridgeMD
Tests treatment safety and results for Lumbar Disc Herniation
Official title The Influence of the Timing of Postoperative Rehabilitation Intervention on the Clinical Efficacy of Unilateral Biportal Endoscopic Spine System in the Treatment of Lumbar Disc Herniation
ClinicalTrials.gov ID: NCT07161232
What this study is testing
- What it's testing
- This study focuses on the impact of the timing of postoperative rehabilitation intervention on the clinical efficacy of unilateral biportal endoscopic spine surgery in the treatment of lumbar disc herniation. The main objective is to explore this impact and provide high-quality evidence-based medical evidence for making reasonable clinical decisions.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 19 to 65
You may be able to join if
- Aged between 19 and 65 years.
- Diagnosed with lumbar disc herniation by imaging and scheduled for unilateral biportal endoscopic (UBE) surgery.
- Presenting with radicular pain in the lower extremity, with a history of less than 1 year.
- Able to understand Chinese and complete questionnaires independently.
- Physically capable of participating in exercise rehabilitation.
You likely can't join if
- Aged under 18 or over 65 years.
- Combined with other spinal pathologies (e.g., ankylosing spondylitis, rheumatoid arthritis, spinal tumor, spinal fracture, cauda equina syndrome).
- Diagnosis of neurological disorders (e.g., multiple sclerosis, Parkinson's disease).
- Presence of uncontrolled cardiovascular, respiratory, or peripheral vascular diseases.
- History of severe psychiatric disorders (e.g., schizophrenia).
- Previous history of spinal surgery.
See the full eligibility criteria
- Aged between 19 and 65 years.
- Diagnosed with lumbar disc herniation by imaging and scheduled for unilateral biportal endoscopic (UBE) surgery.
- Presenting with radicular pain in the lower extremity, with a history of less than 1 year.
- Able to understand Chinese and complete questionnaires independently.
- Physically capable of participating in exercise rehabilitation.
- Willing to participate and provide written informed consent.
- Aged under 18 or over 65 years.
- Combined with other spinal pathologies (e.g., ankylosing spondylitis, rheumatoid arthritis, spinal tumor, spinal fracture, cauda equina syndrome).
- Diagnosis of neurological disorders (e.g., multiple sclerosis, Parkinson's disease).
- Presence of uncontrolled cardiovascular, respiratory, or peripheral vascular diseases.
- History of severe psychiatric disorders (e.g., schizophrenia).
- Previous history of spinal surgery.
- Pregnancy or lactation.
- Inability to understand or comply with the study procedures.
The study team makes the final eligibility decision.
Where it's taking place
- Beijing, Beijing Municipality, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 19 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Beijing, Beijing Municipality, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.